
Imugene Ltd
ASX:IMU

Fundamental Analysis

Substantial clinical risk remains with Imugene’s CF33-based oncolytic virus platform, as disappointing trial results for even one major candidate could undermine investor confidence and derail the company’s broader immuno-oncology pipeline.
Imugene’s multivalent approach to immuno-oncology, highlighted by its CF33 oncolytic virus and HER-Vaxx candidates, offers significant potential breakthroughs in treating various tumor types, positioning the firm as a future leader in next-generation cancer therapies.

Revenue & Expenses Breakdown
Imugene Ltd
Balance Sheet Decomposition
Imugene Ltd
Current Assets | 81.6m |
Cash & Short-Term Investments | 35.3m |
Receivables | 38.2m |
Other Current Assets | 8.1m |
Non-Current Assets | 39.3m |
Long-Term Investments | 2.7m |
PP&E | 3.2m |
Intangibles | 33.2m |
Other Non-Current Assets | 175.1k |
Free Cash Flow Analysis
Imugene Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
Imugene Ltd
Revenue
|
0
AUD
|
Operating Expenses
|
-132.5m
AUD
|
Operating Income
|
-132.5m
AUD
|
Other Expenses
|
3.2m
AUD
|
Net Income
|
-129.3m
AUD
|
IMU Profitability Score
Profitability Due Diligence
Imugene Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.

Score
Imugene Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.
IMU Solvency Score
Solvency Due Diligence
Imugene Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Score
Imugene Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMU Price Targets Summary
Imugene Ltd
Dividends
Current shareholder yield for IMU is
hidden
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?